AWY0.F Percheron Therapeutics Limited

Healthcare Drug Manufacturers - Specialty & Generic Frankfurt Exchange
0.0005 EUR
Close of Nov 11, 2026
0.0005 0.0045
Market cap
EUR 991K
P/E
-
P/B
0.21x
ROE
-63.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is AWY0.F undervalued?

Graham number

The Graham number of Percheron Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Percheron Therapeutics Limited fundamental analysis

No fundamental analysis for Percheron Therapeutics Limited yet.

Percheron Therapeutics Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Percheron Therapeutics Limited

Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in …

Full company profile